263 Views
P7. Maternal-child infections
Oral Abstract Submission
Margaret (Peggy) Honein, PhD
Division Director
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Marcela Mercado, MS
Researcher
Instituto Nacional de Salud
Bogota, Distrito Capital de Bogota, Colombia
Disclosure: Nothing to disclose
Suzanne Gilboa, PhD
Senior Scientist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Diana Valencia, MS
Health Scientist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Marcela Daza, MD
Pediatrician
Instituto Nacional de Salud
Bogota, Distrito Capital de Bogota, Colombia
Disclosure: Nothing to disclose
Romeo Galang, MD
OB/GYN
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Christina Winfield, MPH
Health Scientist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Shana Godfred-Cato, MD
Pediatrician
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Mónica Benavides
Health Scientist
Vysnova
Bogota, Distrito Capital de Bogota, Colombia
Disclosure: Nothing to disclose
Julie Villanueva, PhD
Supervisory Health Scientist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Jonathan Daniels
Microbiologist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Julu Bhatnagar, PhD
Microbiologist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Jarad Schiffer, PhD
Supervisory Health Scientist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Sheryll Corchuelo
Health Scientist
Vysnova
Bogota, Distrito Capital de Bogota, Colombia
Disclosure: Nothing to disclose
Sarah Tinker, PhD
Epidemiologist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Kayla Anderson, PhD
Epidemiologist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Johana Osorio
Health Scientist
Vysnova
Bogota, Distrito Capital de Bogota, Colombia
Disclosure: Nothing to disclose
Jacob Hojnacki, MPH
Fellow
Oak Ridge Institutes for Science and Education
Atlanta, GA
Disclosure: Nothing to disclose
Van Tong, MPH
Epidemiologist
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Maritza Gonzalez, MD
Advisor to the Director
Instituto Nacional de Salud
Bogota, Distrito Capital de Bogota, Colombia
Disclosure: Nothing to disclose
Cynthia Moore, MD, PhD
Chief Medical Officer
Centers for Disease Control and Prevention
Atlanta, GA
Disclosure: Nothing to disclose
Martha Lucia Ospina, MD
Director
Instituto Nacional de Salud
Bogota, Distrito Capital de Bogota, Colombia
Disclosure: Nothing to disclose
Background : Proyecto Vigilancia de Embarazadas con Zika (VEZ) was an intensified surveillance system built upon existing national surveillance of pregnant women with symptoms of Zika virus (ZIKV) disease and conducted in three Colombian cities with high prevalence of Zika. This analysis of data from VEZ estimates the risk of Zika-associated birth defects among pregnant women with symptoms of ZIKV disease, and among a subset with laboratory evidence of possible ZIKV infection during pregnancy.
Methods : During April-November 2016, pregnant women were enrolled if they were reported to the surveillance system (Sivigila) or visited participating clinics with symptoms of ZIKV disease. Maternal and pediatric data were abstracted from prenatal care, ultrasound, and delivery records, as well as from pediatric or specialist visit records. Available maternal and infant specimens were tested for the presence of ZIKV RNA and/or anti-ZIKV immunoglobulin (IgM) antibodies.
Results : Of 1,223 women enrolled, 47.8% and 34.3% reported first or second trimester symptom onset, respectively. Of 381 pregnancies with maternal and/or infant specimens tested, 108 (29%) had laboratory evidence of possible ZIKV infection during pregnancy; half of these (53.3%) were positive for ZIKV RNA only, 37.4% for IgM antibodies only, and 9.3% for both. Of 1,190 of pregnancies with known outcome, 63 (5%) had Zika-associated brain or eye defects; among the subset with any laboratory evidence, 12 (11%) had Zika-associated brain or eye defects. The prevalence of Zika-associated brain or eye defects was 5.9% (35/593) and 4.5% (19/423) among pregnancies with symptom onset in the first and second trimester, respectively.
Conclusion : Among pregnant women with symptoms of ZIKV disease enrolled during the height of the ZIKV epidemic in Colombia, prevalence of any Zika-associated brain or eye defect was 5%, with a higher prevalence among those with laboratory evidence of possible ZIKV infection. Rapid enhancements to Colombia’s national surveillance enabled the estimation of the risk of birth defects associated with ZIKV disease in pregnancy.